Podcast Episodes
Back to SearchBiotech royalty deals on the rise and here to stay
Episode 169
In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, …
1 year ago
Contraline's ADAM in the clinic: towards a new era of male contraception?
Episode 168
When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contrac…
1 year ago
Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play
Episode 167
Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. B…
1 year ago
What’s next in immunology & inflammation R&D: The trends to watch
Episode 166
Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering fro…
1 year ago
BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year
Episode 165
Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, …
1 year ago
AION Labs is building innovative biotechs with top pharma partners in Israel
Episode 164
How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on…
1 year, 1 month ago
Navigating the biotech development journey from first steps to global scale with Lonza
Episode 163
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They …
1 year, 1 month ago
A Finnish biotech is making progress on Parkinson's disease with support from The Michael J. Fox Foundation
Episode 162
Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing s…
1 year, 1 month ago
How RNAi is expanding from a therapy of choice for rare disease into treating common conditions
Episode 161
RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions?
Alnylam was the very first company to…
1 year, 1 month ago
Are next-generation psychedelics the way forward for addressing treatment resistant depression?
Episode 160
Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 t…
1 year, 2 months ago